6 research outputs found
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.
<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p
Hazard ratio for risk of flare: Unadjusted Cox regressions.
<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.
<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.
<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.</p